Napredna pretraga

Pregled bibliografske jedinice broj: 514870

Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response in therapy of NSCLC patients


Pavićević, Radomir, Bubanović, Gordana; Krajna, Ana; Miličić, Jasna; Bialk, Peter; Pavićević, Lukrecija; Stančić-Rokotov, Dinko
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response in therapy of NSCLC patients // European Respiratory Journal / Cosio, M, et al (ur.).
Sheffield: European Respiratory Society, 2001. str. 377s-377s (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response in therapy of NSCLC patients

Autori
Pavićević, Radomir, Bubanović, Gordana ; Krajna, Ana ; Miličić, Jasna ; Bialk, Peter ; Pavićević, Lukrecija ; Stančić-Rokotov, Dinko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Respiratory Journal / Cosio, M, et al - Sheffield : European Respiratory Society, 2001, 377s-377s

ISBN
1-904097-02-2

Skup
11th ERS annual congress

Mjesto i datum
Berlin, Njemačka, 22-26.9.2001

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
CYFRA 21-1; NSCLC

Sažetak
In this study we presented the dynamics of tumor marker CYFRA 21-1 level that is evaluyted as a response to therapy (surgery and chemotherapy) in 500 NSCLC patients. Serum level of CYFRA 21-1 was measured with electrochemiluminescence method using fully automated system Elecsys 2010 (Roche Diagnostics). The level of CYFRA 21-1 in NSCLC patients was determined before and after the therapy. In 95% surgically treated patients we observed a significant decrease of CYFRA 21-1 level after the therapy to the average level of healthy population (p<0, 001). In 5% patients the increase of CYFRA 21-1 level was observed after the surgery which indicated the tumor biological activity. This allowed the clinicians to apply an additional therapy. From 141 patients who underwent surgery followed by chemotherapy in 35% CYFRA 21-1 level indicated the inefficiency of therapy which was also proved clinically. This allowed the clinicians to replace the applied chemotherapy. Introducing the protocol including the evaluation of CYFRA 21-1 level before and after therapy we proved the contribution of tumor marker CYFRA 21-1 to the selection and control of therapy and the assessment of therapy efficiency.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Kliničke medicinske znanosti



POVEZANOST RADA


Časopis indeksira:


  • Scopus
  • MEDLINE